Immunology market size to grow by USD 56.07 billion from 2022-27

The global immunology market size is estimated to grow by USD 56.07 billion from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 8.84% and the growth momentum will progress during the forecast period. North America is estimated to account for 41% of the global market growth. The market is expected to register moderate growth during the forecast period owing to the increased funding from government and non-government bodies along with the rise in the prevalence rate of chronic diseases such as rheumatoid arthritis and cancer. According to the CDC, in January 2021, the incidence rate of female breast cancer was 123.9 per 100,000 people in the US. These drug trials revealed that the effect of anti-cancer drugs lasts longer when immuno-booster drugs are given along with the anti-cancer drugs.

Immunology market – Segmentation assessment
Segment overview
Technavio has segmented the market based on type (immunosuppressants and immuno boosters), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW)).

The market share growth by the immunosuppressants segment will be significant for overall market growth during the forecast period. These drugs have a large number of applications in organ transplantation where the chances of organ rejection are high. Since the body’s immune system identifies the new organ as a foreign agent and tends to attack it, resulting in rejection because the immune system perceives transplanted organs as foreign items and mounts an immunological response against them. This causes the organs to be destroyed while also affecting other body components.

Immunology market – Market dynamics
Key factor driving market growth

• Hurdles in the approval of biosimilars are the major factors driving the growth of the global immunology market.
• The clearance of biosimilars from the US FDA is slow, as obtaining guidance documents for a biosimilar is time-consuming.
• For instance, INFLECTRA was cleared by the US FDA after two months of House Subcommittee hearings.
• And as per the Biologics Price Competition and Innovation (BPCI) Act, it is not essential for the US FDA to issue guidance before approving a biosimilar application.
• However, this guide will help to ensure successful implementation.
• Hence, such factors drive market growth during the forecast period.

Leading trends influencing the market 

• A significant pipeline of immunology is the primary trend in the global immunology market growth.
• There are multiple promising immunological agents in the pipeline.
• This will boost market growth after their approval and the approval of a new treatment increases treatment options and increases demand for that treatment regimen.
• Furthermore, around 51 molecules are in various stages of clinical trials worldwide. Of these, 22 molecules are in Phase II, four are in Phase III, 16 are in Phase I, and the rest are in Phase I/II clinical trials.
• Hence, these developments will lead to the global immunology market growth during the forecast period.

Major challenges hindering the market growth

• Lack of awareness of immunology is a major challenge hindering the growth of the global immunology market.
• There is a significant lack of awareness among people about fatigue as a serious symptom of rheumatoid arthritis.
• In spite of its high prevalence, allergies are still underdiagnosed and undertreated due to a lack of information.
• The NIH also states that more than one-third of patients who experience rhinitis and asthma symptoms remain undiagnosed and have decreased their quality of life.
• Hence, the lack of awareness is a major challenge and is likely to hinder the global immunology market during the forecast period.

Technavio